Accurate coding for menopause is essential for clinical clarity, proper reimbursement, and regulatory compliance. Menopause and related climacteric states are common reasons for outpatient encounters in primary care, gynecology, and endocrinology. Selecting the correct ICD-10-CM code impacts medical necessity assertions, care pathways, and claim adjudication.
This guide explains the ICD-10 code assignment for menopause, clinical definitions, specific scenarios when N95.1 is appropriate or inappropriate, related diagnosis codes to consider, and pragmatic documentation and billing strategies to reduce denials. It is written for coders, billers, clinical documentation improvement (CDI) specialists, and revenue cycle managers.
The ICD-10-CM Code for Menopausal and female climacteric states is N95.1.
Menopause, clinically, is the permanent cessation of menstruation resulting from loss of ovarian follicular function. It is typically diagnosed retrospectively after 12 consecutive months of amenorrhea not due to other causes. The term "Menopausal and female climacteric states" encompasses natural menopause, perimenopausal symptoms, and the broader physiologic transition characterized by hormonal changes and associated vasomotor, genitourinary, and psychosocial symptoms. In ICD-10-CM, N95.1 is used to indicate menopausal status or climacteric state when documented and when no more specific complication code is appropriate.
Use N95.1 when a clinician documents menopause or "postmenopausal status" during an annual exam or preventive visit as part of the problem list or assessment. If no acute complication, symptom management, or procedure is being billed separately, N95.1 appropriately captures the patient's menopausal status for continuity of care and population health reporting.
Use N95.1 when the visit is for menopausal symptoms that the clinician attributes to menopause (hot flashes, night sweats) and documents that the symptoms are related to the climacteric state. If symptom-directed therapy (hormone therapy, nonhormonal pharmacotherapy) is started or adjusted and the encounter centers on menopause, N95.1 supports medical necessity.
When the clinician documents ongoing management of menopause — for example, initiation or titration of hormone replacement therapy, counseling about risks and benefits, or monitoring side effects — code N95.1 is appropriate as the primary diagnosis for the medication management encounter.
If a clinician documents perimenopause or the climacteric transition as the primary diagnosis, and there is no separate specific etiologic condition, use N95.1 to reflect the physiologic status and related management decisions.
Do not use N95.1 when the clinician documents a specific complication attributable to menopause, such as genitourinary syndrome of menopause (GSM) or osteoporotic fracture. Instead, use the more specific code that describes the complication (for example, codes for atrophic vaginitis or osteoporosis) as primary, with N95.1 as a secondary if needed for context.
If the presenting symptoms (e.g., hot flashes, mood changes) are attributed to a medication side effect, thyroid dysfunction, or another endocrine disorder, code the underlying cause rather than N95.1. Documentation must clearly link symptoms to menopause to justify N95.1.
For encounters focused on screening, procedures, or lab testing unrelated to menopausal management (e.g., Pap smear, bone density screening), use the screening or procedural diagnosis when required by payer policy; N95.1 may be appended as secondary if relevant to medical history.
Avoid using N95.1 if the chart contains vague language such as "changes in menses" without clinician confirmation of menopause or perimenopause. Request clarification or addendum to specify menopausal status; otherwise, code to the documented symptom (e.g., amenorrhea) with appropriate supporting codes.
| Condition | Code | When It Is Used | When It Is Not Used |
|---|---|---|---|
| Menopausal and female climacteric states | N95.1 | Use when clinician documents menopause, perimenopause, or climacteric state as primary reason for visit or management (e.g., HRT initiation, counseling, vasomotor symptoms attributed to menopause). | Do not use when a specific complication or alternate primary diagnosis explains symptoms; use the specific complication or underlying condition instead. |
| Atrophic vaginitis (genitourinary syndrome of menopause) | N95.2 | Use when clinician documents atrophic changes of the vagina or vulva attributed to menopause with local symptoms such as dryness, dyspareunia, or recurrent urinary symptoms. | Do not use when only menopausal status is documented without genitourinary symptoms; use N95.1 instead. |
| Menopausal and postmenopausal osteoporosis | M80.- / M81.- | Use when osteoporosis is diagnosed with or without fracture in the postmenopausal patient—select M80 if there is pathological fracture, M81 for osteoporosis without current fracture. | Do not use N95.1 as a substitute for osteoporosis coding; use N95.1 only as secondary to indicate menopausal status if clinically relevant. |
| Other specified menopausal and female climacteric states | N95.8 | Use for other specified menopausal conditions not captured by N95.1 or N95.2 when documentation describes a specific menopausal disorder that does not fit established categories. | Do not use N95.8 if classic menopausal status is documented and fits N95.1; choose the most specific applicable code. |
Explicitly state when symptoms (hot flashes, vaginal dryness, sleep disturbance) are attributable to menopause. Documentation that links symptom to menopausal transition supports N95.1 and medical necessity for treatment.
Select the code that best explains the visit. If a specific complication is present, code that as primary and append N95.1 as secondary when relevant. Proper sequencing reduces denials for lack of medical necessity.
When managing hormone therapy or nonhormonal treatments, document dosage changes, informed consent, counseling on risks/benefits, and monitoring plans. This substantiates the visit complexity and supports reimbursement for evaluation/management or procedure codes.
Ensure the electronic health record problem list aligns with visit documentation. Update menopausal status consistently to prevent conflicting codes across encounters that can trigger payer reviews.
Leverage CombineHealth.ai’s AI-powered platform features such as automated claim scrubbing and coding validation to identify mismatches between diagnosis codes, procedure codes, and documented clinical indicators. CombineHealth.ai’s denial management capabilities help reduce preventable rejections and improve first-pass acceptance.
Coding for menopause has direct impact on revenue cycle outcomes:
Accurate ICD-10 coding is critical for healthcare revenue cycle performance. CombineHealth.ai's AI-powered platform helps RCM teams ensure coding accuracy, reduce denials, and optimize reimbursement through intelligent denial management and claim validation. CombineHealth.ai's intelligent platform provides automated claim scrubbing and coding validation to catch errors before submission, reducing denials and improving first-pass acceptance rates.
Q1: What is the ICD-10 code for menopause?
The ICD-10-CM code for Menopausal and female climacteric states is N95.1. Use it when a clinician documents menopause, perimenopause, or climacteric state as the reason for evaluation or management and no more specific complication code better describes the encounter.
Q2: When should I use N95.1 vs related codes?
Use N95.1 for menopausal status or symptomatic management of the climacteric transition. Use related codes—such as atrophic vaginitis or postmenopausal osteoporosis—when specific genitourinary or skeletal complications are documented; sequence the complication as primary and N95.1 as secondary if the menopausal state provides context.
Q3: What documentation is required when coding for menopause?
Document the diagnosis (menopause, perimenopause), the symptoms and their relationship to menopause, assessment, and treatment plan. For hormone therapy, include counseling notes, informed consent, dosing, and monitoring plans. Include objective findings when relevant (e.g., bone density, labs).
Q4: What are common denial reasons when coding for menopause?
Denials commonly arise from non-specific documentation, lack of linkage between symptoms and menopausal status, coding N95.1 when a complication code should be used, and missing prior authorization for treatments. See our guide on denial management for strategies to mitigate these risks.